Do analysts rate CRDL or GNTA?

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 593.88%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CRDL or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is CRDL or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Genenta Science N/A N/A N/A

Do analysts recommend GNTA or HURA?

TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 318.60%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, GNTA or HURA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is GNTA or HURA more profitable?

Genenta Science's return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A TuHURA Biosciences N/A -156.12% -105.38%

Do analysts recommend GNTA or UNCY?

Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 327.64%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Unicycive Therapeutics 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has preferable valuation and earnings, GNTA or UNCY?

Genenta Science has higher earnings, but lower revenue than Unicycive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Unicycive Therapeutics $680K 204.86 -$26.56M -$2.21 N/A

Is GNTA or UNCY more profitable?

Genenta Science's return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Unicycive Therapeutics N/A -134.69% -84.51%

Do analysts recommend GNTA or CNTB?

Connect Biopharma has a consensus target price of $7.29, suggesting a potential upside of 251.12%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has higher valuation & earnings, GNTA or CNTB?

Genenta Science has higher earnings, but lower revenue than Connect Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Connect Biopharma $233K 560.73 -$55.48M -$1.15 N/A

Is GNTA or CNTB more profitable?

Genenta Science's return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Connect Biopharma N/A -122.29% -97.07%

Do analysts prefer GNTA or NGEN?

NervGen Pharma has a consensus target price of $14.00, indicating a potential upside of 737.32%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83

Which has preferable valuation and earnings, GNTA or NGEN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is GNTA or NGEN more profitable?

Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A NervGen Pharma N/A N/A N/A

Genenta Science (GNTA) Competitors

$1.48 -0.01 (-0.74%)

As of 11:12 AM Eastern

Compare

GNTA vs. CRDL, HURA, UNCY, CNTB, and NGEN

Should you buy Genenta Science stock or one of its competitors? MarketBeat compares Genenta Science with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genenta Science include Cardiol Therapeutics (CRDL), TuHURA Biosciences (HURA), Unicycive Therapeutics (UNCY), Connect Biopharma (CNTB), and NervGen Pharma (NGEN).

How does Genenta Science compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Cardiol Therapeutics had 10 more articles in the media than Genenta Science. MarketBeat recorded 10 mentions for Cardiol Therapeutics and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.00 beat Cardiol Therapeutics' score of -0.07 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Genenta Science	Neutral

Genenta Science's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Genenta Science	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 593.88%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

Genenta Science beats Cardiol Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Genenta Science compare to TuHURA Biosciences?

Genenta Science (NASDAQ:GNTA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Genenta Science's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.12%	-105.38%

TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 318.60%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genenta Science has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

In the previous week, TuHURA Biosciences had 2 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for TuHURA Biosciences and 0 mentions for Genenta Science. TuHURA Biosciences' average media sentiment score of 0.80 beat Genenta Science's score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
TuHURA Biosciences	Positive

Summary

Genenta Science beats TuHURA Biosciences on 6 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Unicycive Therapeutics?

Genenta Science (NASDAQ:GNTA) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Genenta Science has higher earnings, but lower revenue than Unicycive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Unicycive Therapeutics	$680K	204.86	-$26.56M	-$2.21	N/A

In the previous week, Genenta Science's average media sentiment score of 0.00 equaled Unicycive Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
Unicycive Therapeutics	Neutral

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genenta Science's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 327.64%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Genenta Science has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Summary

Unicycive Therapeutics beats Genenta Science on 6 of the 10 factors compared between the two stocks.

How does Genenta Science compare to Connect Biopharma?

Genenta Science (NASDAQ:GNTA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Genenta Science has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its stock price is 123% less volatile than the broader market.

In the previous week, Connect Biopharma had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for Connect Biopharma and 0 mentions for Genenta Science. Connect Biopharma's average media sentiment score of 1.36 beat Genenta Science's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Connect Biopharma	Positive

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Connect Biopharma has a consensus target price of $7.29, suggesting a potential upside of 251.12%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Genenta Science's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Connect Biopharma	N/A	-122.29%	-97.07%

Genenta Science has higher earnings, but lower revenue than Connect Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Connect Biopharma	$233K	560.73	-$55.48M	-$1.15	N/A

Summary

Connect Biopharma beats Genenta Science on 7 of the 12 factors compared between the two stocks.

How does Genenta Science compare to NervGen Pharma?

Genenta Science (NASDAQ:GNTA) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, Genenta Science's average media sentiment score of 0.00 equaled NervGen Pharma'saverage media sentiment score.

Company	Overall Sentiment
Genenta Science	Neutral
NervGen Pharma	Neutral

15.1% of Genenta Science shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NervGen Pharma has a consensus target price of $14.00, indicating a potential upside of 737.32%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A

Summary

NervGen Pharma beats Genenta Science on 4 of the 6 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNTA vs. The Competition

Export

Metric	Genenta Science	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.68M	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	N/A	7.39	282.14	25.05
Price / Sales	N/A	1,212.47	573.43	80.07
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.15	17.11	11.09	6.19
Net Income	-$7.39M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-6.98%	-0.59%	0.42%	0.74%
1 Month Performance	-14.01%	-7.44%	-4.33%	-3.72%
1 Year Performance	-60.31%	49.84%	63.09%	20.27%

Genenta Science Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNTA Genenta Science	0.5937 of 5 stars	$1.48 -0.7%	N/A	-60.0%	$34.68M	N/A	N/A	7	Gap Up
CRDL Cardiol Therapeutics	2.5583 of 5 stars	$1.16 -3.3%	$8.50 +632.1%	-8.0%	$134.27M	N/A	N/A	20	Positive News
HURA TuHURA Biosciences	1.6819 of 5 stars	$2.10 -1.6%	$9.00 +329.6%	-9.6%	$133.41M	N/A	N/A	N/A
UNCY Unicycive Therapeutics	2.2932 of 5 stars	$4.83 -2.3%	$21.75 +350.7%	+19.3%	$132.43M	$680K	N/A	9
CNTB Connect Biopharma	4.4064 of 5 stars	$2.10 +0.7%	$7.29 +247.8%	+1.0%	$131.90M	$60K	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genenta Science (GNTA) Competitors

GNTA vs. CRDL, HURA, UNCY, CNTB, and NGEN

How does Genenta Science compare to Cardiol Therapeutics?

Summary

How does Genenta Science compare to TuHURA Biosciences?

Summary

How does Genenta Science compare to Unicycive Therapeutics?

Summary

How does Genenta Science compare to Connect Biopharma?

Summary

How does Genenta Science compare to NervGen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genenta Science (GNTA) Competitors

GNTA vs. CRDL, HURA, UNCY, CNTB, and NGEN

How does Genenta Science compare to Cardiol Therapeutics?

Does the media prefer CRDL or GNTA?

Is CRDL or GNTA more profitable?

Which has higher valuation & earnings, CRDL or GNTA?

Do analysts rate CRDL or GNTA?

Do institutionals and insiders hold more shares of CRDL or GNTA?

Which has more risk and volatility, CRDL or GNTA?

Summary

How does Genenta Science compare to TuHURA Biosciences?

Is GNTA or HURA more profitable?

Do analysts recommend GNTA or HURA?

Do institutionals and insiders hold more shares of GNTA or HURA?

Which has more volatility & risk, GNTA or HURA?

Which has stronger valuation and earnings, GNTA or HURA?

Does the media favor GNTA or HURA?

Summary

How does Genenta Science compare to Unicycive Therapeutics?

Which has preferable valuation and earnings, GNTA or UNCY?

Does the media refer more to GNTA or UNCY?

Do institutionals and insiders hold more shares of GNTA or UNCY?

Is GNTA or UNCY more profitable?

Do analysts recommend GNTA or UNCY?

Which has more volatility & risk, GNTA or UNCY?

Summary

How does Genenta Science compare to Connect Biopharma?

Which has more volatility and risk, GNTA or CNTB?

Does the media favor GNTA or CNTB?

Do insiders and institutionals have more ownership in GNTA or CNTB?

Do analysts recommend GNTA or CNTB?

Is GNTA or CNTB more profitable?

Which has higher valuation & earnings, GNTA or CNTB?

Summary

How does Genenta Science compare to NervGen Pharma?

Which has preferable valuation and earnings, GNTA or NGEN?

Does the media refer more to GNTA or NGEN?

Do insiders & institutionals hold more shares of GNTA or NGEN?

Do analysts prefer GNTA or NGEN?

Is GNTA or NGEN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools